Status:
COMPLETED
Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
Lead Sponsor:
Rabin Medical Center
Conditions:
Parkinson Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.
Eligibility Criteria
Inclusion
- clinical diagnosis with PD
- subjects who are willing to participate in the trial.
- subjects who participated in the BIA 9-1067-302 clinical trial.
Exclusion
- subjects who didn't take part at the BIA 9-1067-302 clinical trial.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 24 2016
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01851850
Start Date
May 1 2013
End Date
May 24 2016
Last Update
March 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petach Tiqva, Central District, Israel, 49100